β受体阻滞剂对血脂正常或血脂异常的高血压患者血清脂质和载脂蛋白影响的差异。
Differentiation of beta-blocker effects on serum lipids and apolipoproteins in hypertensive patients with normolipidaemic or dyslipidaemic profiles.
作者信息
Vyssoulis G P, Karpanou E A, Pitsavos C E, Skoumas J N, Paleologos A A, Toutouzas P K
机构信息
Department of Cardiology, University of Athens, Hippokration General Hospital, Greece.
出版信息
Eur Heart J. 1992 Nov;13(11):1506-13. doi: 10.1093/oxfordjournals.eurheartj.a060093.
To evaluate the differential effects of beta-blockers on serum lipids and apolipoproteins in normolipidaemic and dyslipidaemic hypertensives, 330 patients with mild to moderate essential hypertension were studied 1 month after placebo therapy and 6 months after monotherapy with propranolol (n = 53), atenolol (n = 66), metoprolol (n = 58), pindolol (n = 53), or celiprolol (n = 100). Serum total cholesterol, triglycerides, high density lipoprotein-cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C), and apolipoproteins (Apo) A1 and B were measured at baseline and study end. A total of 136 (41.2%) patients were considered normolipidaemic (pretreatment LDL-C < 160 mg.dl-1) and 194 (58.8%) were considered dyslipidaemic (LDL-C > 160 mg.dl-1). Changes in total cholesterol differed between normolipidaemics and dyslipidaemics with propranolol (+13% in normolipidaemics vs -0.5% in dyslipidaemics, P < 0.001), atenolol (+7% vs -2%, P = 0.01), metoprolol (+9% vs -4%, P0.0006), pindolol (+8% vs -9%, P < 0.001), and celiprolol (-1% vs -13%, P = 0.002). HDL-C differed less, with propranolol (-18% vs -13%), atenolol (-6% vs -2%), metoprolol (-2% vs -6%), pindolol (+4% vs +1%), and celiprolol (+9% vs +4%); none of these changes between normolipidaemic and dyslipidaemic patients were statistically significant. LDL-C changes differed the most, with propranolol (+35% vs -1%, P < 0.0001), atenolol (+15% vs -4%, P = 0.001), metoprolol (+12% vs -6%, P = 0.004), pindolol (+12% vs -13%, P < 0.0001), and celiprolol (+3% vs -16%, P = 0.0001).(ABSTRACT TRUNCATED AT 250 WORDS)
为评估β受体阻滞剂对血脂正常和血脂异常高血压患者血清脂质及载脂蛋白的不同影响，我们对330例轻至中度原发性高血压患者进行了研究。这些患者在接受安慰剂治疗1个月后，以及接受普萘洛尔（n = 53）、阿替洛尔（n = 66）、美托洛尔（n = 58）、吲哚洛尔（n = 53）或塞利洛尔（n = 100）单药治疗6个月后进行观察。在基线和研究结束时测量血清总胆固醇、甘油三酯、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）以及载脂蛋白A1和B。共有136例（41.2%）患者被视为血脂正常（治疗前LDL-C < 160 mg·dl⁻¹），194例（58.8%）患者被视为血脂异常（LDL-C > 160 mg·dl⁻¹）。血脂正常和血脂异常患者使用普萘洛尔后总胆固醇变化不同（血脂正常者升高13%，血脂异常者降低0.5%，P < 0.001），阿替洛尔（升高7% 对降低2%，P = 0.01），美托洛尔（升高9% 对降低4%，P = 0.0006），吲哚洛尔（升高8% 对降低9%，P < 0.001），塞利洛尔（降低1% 对降低13%，P = 0.002）。HDL-C变化差异较小，普萘洛尔（降低18% 对降低13%），阿替洛尔（降低6% 对降低2%），美托洛尔（降低2% 对降低6%），吲哚洛尔（升高4% 对升高1%），塞利洛尔（升高9% 对升高4%）；血脂正常和血脂异常患者之间的这些变化均无统计学意义。LDL-C变化差异最大，普萘洛尔（升高35% 对降低1%，P < 0.0001），阿替洛尔（升高15% 对降低4%，P = 0.001），美托洛尔（升高12% 对降低6%，P = 0.004），吲哚洛尔（升高12% 对降低13%，P < 0.0001），塞利洛尔（升高3% 对降低16%，P = 0.0001）。（摘要截选至250词）
Zotero 插件